Topic

Cigna

A collection of 1134 issues

How to Get Epidiolex (Cannabidiol) Covered by Cigna in Ohio: Complete Guide to Prior Authorization, Appeals, and Timelines

Answer Box: Getting Epidiolex Covered by Cigna in Ohio Yes, Cigna covers Epidiolex for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex seizures, but requires prior authorization through Express Scripts. Fastest path: Have your neurologist submit PA with documented diagnosis, failed trials of 2+ antiseizure medications, and baseline liver function
6 min read

How to Get Sylvant (Siltuximab) Covered by Cigna in Georgia: Prior Authorization, Appeals, and State Review Process

Answer Box: Getting Sylvant (Siltuximab) Covered by Cigna in Georgia Cigna requires prior authorization for Sylvant (siltuximab) with strict documentation including HIV-negative and HHV-8-negative test results plus pathology confirming idiopathic multicentric Castleman disease. HMO members need specialist referrals first; PPO/EPO members can go directly to oncology/hematology. If denied,
5 min read

Myths vs. Facts: Getting Signifor / Signifor LAR (pasireotide) Covered by Cigna in New York

Answer Box: Getting Signifor / Signifor LAR Covered by Cigna in New York Eligibility: Cigna requires prior authorization for Signifor / Signifor LAR with strict criteria: confirmed Cushing's disease or acromegaly, endocrinologist prescription, documented failure of first-generation somatostatin analogs (for acromegaly), and surgical ineligibility or post-surgical persistence. Fastest path: Submit
6 min read

How to Get Opzelura (Ruxolitinib Cream) Covered by Cigna in Pennsylvania: Complete Appeals Guide with Forms and Timelines

Answer Box: Getting Opzelura Covered by Cigna in Pennsylvania Fastest Path to Approval: Cigna requires prior authorization for Opzelura (ruxolitinib cream) with mandatory step therapy. You must document failed trials of topical corticosteroids (≥28 days) AND calcineurin inhibitors (≥12 weeks) before approval. If denied, Pennsylvania's new external review
6 min read